Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor (GM-CSF)

Leukemia Research

Volumn 20, Issue 5, 1996, Pages 385-390

  Economopoulos, Theofanis ^a,c   Papageorgiou, Efstathios ^a   Stathakis, Nicholas ^b   Constantinidou, Maria ^a   Parharidou, Agapi ^a   Kostourou, Akrivi ^a   Dervenoulas, John ^a   Raptis, Sotos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Larissa University   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Chemotherapy; GM CSF; High risk myelodysplastic syndromes; Treatment

Indexed keywords

CYTARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN;

ADULT; AGED; ARTICLE; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG FATALITY; DRUG TOXICITY; FEMALE; FEVER; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; INFECTION; LEUKOCYTE COUNT; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; REMISSION; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; TREATMENT FAILURE;

EID: 0029995435     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/0145-2126(95)00169-7     Document Type: Article

References (36)

1. Economopoulos T., Stathakis N., Foudoulakis A., Papadoulis N., Dervenoulas J., Papageorgiou E., Anastassiou C., Hadjioannou J. & Raptis S. (1987) Myelodysplastic syndromes: analysis of 131 cases according to the FAB classification. Eur. J. Haematol. 38, 338.
2. Mufti G. J., Stevens J. R., Oscier D. C., Hamblin T. J. & Machin D. (1985) Myelodysplastic syndromes: a scoring system with prognostic significance. Br. J. Haematol. 59, 425.
3. Aul C., Gattermann N., Heyll A., Germing U., Derigs G. & Schneider W. (1992) Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6, 52.
4. Morel P., Hebbar M., Lai J. L., Duhamel A., Preudhomme C., Wattel E., Bauters F. & Fenaux P. (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report of 408 cases. Leukemia 7, 1315.
5. De Witte T. (1994) New treatment approaches for myelodysplastic syndrome and secondary leukemias. Ann. Oncol. 5, 401.
6. Fenaux P., Morel P., Rose C., Lai J. L., Jouet J. P. & Bauters F. (1991) Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br. J. Haematol. 77, 497.
7. Preisler H. D., Raza A., Barcos M., Azarnia N., Larson R., Browman G., Walker I., Grunwald H., D'Arrigo P., Stein A., Bloom M., Coldberg J., Gottlieb A., Bennett J., Kirshner J. & Priore R. (1986) High dose cytosine arabinoside in the treatment of preleukemia disorders. A leukemia intergroup study. Am. J. Haematol. 23, 131.
8. De Witte T., Muus P., De Pauw P. & Haanen C. (1990) Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer 66, 831.
9. Economopoulos T., Papageorgiou E., Stathakis N., Asprou N., Karmas P., Dervenoulas J., Bouronikou H., Chalevelakis G. & Raptis S. (1992) Treatment of myelodysplastic syndromes with human granulocytic-macrophage colony stimulating factor (GM-CSF) or GM-CSF combined with low dose cytosine arabinoside. Eur. J. Haematol. 49, 138.
10. Buchner T., Hiddemann W., Koenigsmann M., Zuhlsdorf M., Wormann B., Boeckmann A., Aguion Freire E., Inning G., Maschmeyer G., Ludwig W. D., Sauerland M. C., Heinecke A. & Schultz G. (1991) Recombinant human granulocyte-macrophage colony stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78, 1190.
11. Harousseau J. L., Reiffers J., Hurteloup P., Milpied N., Guy H., Rigal-Hugue F., Facon T., Dufour P. & Ifrah N. For the French study group of idarubicin in leukemia. (1989) Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate dose cytarabine. J. Clin. Oncol. 7, 45.
12. Berman E., Heller G., Santorsa J. A., Mckenzie S., Gee T., Kempin S., Gulati S., Andreff M., Kolitz J., Gabrilove J., Reich L., Mayer K., Keefe D., Trainor K., Schluger A., Penenberg D., Raymond U., O' Reilly R., Jhanwar S., Young C. & Clarkson B. (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myeloid leukemia. Blood 77, 1666.
13. Reiffers J., Rigal-Huguet F., Stoppa A. M., Michallet M., Marit G., Attal M., Gastaut B., Lepen G., Routy M., Cony-Mackhoul P., Pris J., Hollard D., Maraninchi-Mercier M. & Hurteloup P. For the BGMT group. (1991) Prospective study comparing idarubicin and daunorubicin in elderly patients with acute myeloid leukemia. Haematol. Blood Trans. 34, 624.
14. Anderlini P., Kantarjian H., Andreeff M., Kornblau S., O'Brien S., Pierce S., Benjamin R. & Estey E. (1994) Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. Blood 84 (Suppl.), 305 (Abstract 1206).
15. Carella A. M., Carlier P., Pungolino F., Resegotti L., Liso V., Stasi R., Montillo M., Lacopino P., Mirto S., Pagano L., Leoni F., Martelli F. M., Di Raimondo F., Porcellini A., De Riu L., Nosari A. M., Cimino R., Damasio E., Miraglia E., Fioritoni G., Ricciuti F., Carotenuto M., Longinotti M., Defazio D., Fazi P. & Mandelli F. For the GINEMA Cooperative Group. (1993) Idarubicin in combination with intermediate dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. Leukemia 78, 196.
16. Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A. G., Gralnick H. R. & Sultan C. (1982) Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51, 189.
17. Ganser A., Volkers B., Greher J., Ottman O. G., Walther F., Becher R., Bergmann L., Schultz G. & Hoelzer D. (1989) Recombinant human granulocyte-macrophage colony stimulating factor in patients with myelodysplastic syndromes - a phase I-II trial. Blood 73, 31.
18. Najean Y. & Pecking A. (1979) Refractory anaemia with excess of myeloblasts in the bone marrow: a clinical trial of androgens in 90 patients. Br. J. Haematol. 37, 25.
19. Clark R. E., Ismail S. A. D., Jacobs A., Payne H. & Smith S. A. (1987) A randomized trial of 13-cis retinoid acid with or without cytosine-arabinoside in patients with myelodysplastic syndromes. Br. J. Haematol. 66, 77.
20. Stadtmauer E. A., Cassileth P. A., Edelstein M., Abraham J., Schreiber A. D., Nowell P. C. & Cines D. B. (1991) Danazol treatment of myelodysplastic syndromes. Br. J. Haematol. 77, 502.
21. Miller K. B., Kyungmann K., Morrison F. S., Winter J. N., Bennett J. M., Neiman R. S., Head D. R., Cassileth P. A. & O'Connell M. J. (1992) The evaluation of low dose cytarabine in the treatment of myelodysplastic syndromes: a phase III intergroup study. Ann. Haematol. 65, 162.
22. Mertelsmann R., Thaler H. T., To L., Gee T. S., McKenzie S., Schauer P., Friedman A., Arlin Z., Cirrincione C. & Clarkson B. (1980) Morphological classification response to therapy and survival in 263 adult patients with acute nonlymphocytic leukemia. Blood 56, 773.
23. Cheson B. D. (1992) Current approaches to the therapy of the myelodysplastic syndromes. Hematol. Rev. 6, 157.
24. Anderson J. E., Appelbaum F. R., Fisher L. D., Schoch G., Anasetti C., Bensinger W. I., Bryant E., Buckner C. D., Doney C., Martin P. C., Sanders J. E., Sullivan K., Thomas D., Witherspoon R. P., Hansen J. A. & Storb R. (1993) Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndromes. Blood 82, 677.
25. Holmes J., Jacobs A., Carter G., Janowska-Wieczorek A. & Padua R. A. (1989) Multidrug resistance in haematopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia. Br. J. Haematol. 72, 40.
26. Willemze R., Lely N. van der, Zwierzina H., Suciu G., Gerhartz H., Labar B., Visani G., Peetermans M., Jacobs A., Stryckmans P., Fenaux P., Haak H. L., Ribeiro M. M., Baumelou E., Baccarani M., Mandelli F., Taksic B., Louwagie A., Thyss A., Hayat M., Cataldo F. de, Stern A. C. & Zittoun R. On behalf of the EORTC Leukemia Cooperative Group. (1992) A randomized phase I/II multicenter study of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. Ann. Hematol. 64, 173.
27. Gerhartz H. H., Marcus R., Delmer A., Zwierzina H., Suciu S., Dardenne M., Solbu G., De Witte T., Jacobs A., Visani G., Fiere D., Sonneveld P., Labar B., Hoffbrand A. V., Fenaux P., Hayat M., Thyss A., Debusscher L., Coiffier B., Sizoo W., Willemze R., Ribeiro M., Mandelli F., Burghouts G., Cauchie C., Peetermans M., Roozendaal K. J., Goudsmit R., Douer D., Castoldi G. L., Stern A. & Zittun R. On behalf of the EORTC Leukemia Cooperative Group. (1994) A randomized phase II study of low dose cytosine arabinoside plus granulocyte-macrophage colony stimulating factor in myelodysplastic syndromes with a high risk of developing leukemia. Leukemia 8, 16.
28. Bernell P., Kimby E. & Hast R. (1994) Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study. Leukemia 8, 1631.
29. Estey E., Thall P., Andreeff M., Beran M., Kantarjian H., O' Brien S., Escudier S., Robertson L. E., Koller C., Kornblau S., Pierce S., Freireich E. J., Deisseroth A. & Keating M. (1994) Use of granulocytic colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J. Clin. Oncol. 12, 671.
30. Tricot G. & Boogaerts M. A. (1986) The role of aggressive chemotherapy in the treatment of myelodysplastic syndromes. Br. J. Haematol. 63, 477.
31. Aul C. & Schneider W. (1989) The role of low dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes. Cancer 64, 1812.
32. Michels S., Saumur J., Arthur D., Robinson L. & Brunning R. (1989) Refractory anemia with excess of blasts in transformation. Haematologic and clinical study of 52 patients. Cancer 64, 2340.
33. Loffler H., Schmitz N. & Gassmann W. (1992) Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Hematol./Oncol. Clins N. Am. 6, 619.
34. Bernasconi C., Lazzarino M., Canevari A., Morra E., Alessandrino E. P., Bernasconi P., Bonfichi M., Caldera D., Boni M. & Troletti D. (1994) Intensive chemotherapy with or without G-CSF in high risk myelodysplastic syndromes or acute leukemia evolving from MDS. Randomised clinical study. Leukemia Res. 18 (Suppl.), 65 (Abstract).
35. Estey E., Kantarjian H., O' Brien S., Beran M., Pierce S., Freireich E. & Keating M. (1994) Treatment of myelodysplasia with AML-type chemotherapy. Proc. Am. Soc. Clin. Oncol. 314 (Abstract 1031).
36. Demuynck H., Delforge M., Verhoef G. E. G., Vandenberghe P., Zachee P. & Boogaerts M. A. (1994) Autologous peripheral blood progenitor cell transplantation as an alternative treatment option for patients with myelodysplastic syndromes. Blood 84 (Suppl.), 86 (Abstract 336).